Interest of Myo-inositol in polycystic ovary syndrome

Polycystic ovary syndrome is the most common endocrinopathy in adolescents and women and is the leading cause of anovulation and infertility. This syndrome combines clinical and/or biological hyperandrogenism with dysovulation and infertility. The exact etiology of PCOS is unknown and is likely multifactorial. Its diagnosis is based on consensual diagnostic criteria, which will probably evolve in the near future with the increasing interest and feasibility of new markers such as AMH. Its management depends on the patient's complaint but, because of the frequency of overweight and associated insulin resistance, must never forget the screening and management of metabolic comorbidities. The various data in the literature and studies are reopening the possibility of using insulin-sensitizing agents in the management of patients with PCOS, in particular by using natural products such as Myo-inositol. It improves the clinical and metabolic profile of women with PCOS with better tolerance.